Treatment of nausea and vomiting: Gaps in our knowledge

Autonomic Neuroscience: Basic and Clinical

Volumn 129, Issue 1-2, 2006, Pages 3-16

  Sanger, Gareth J ^a   Andrews, Paul L R ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

5 Hydroxytryptamine; Cannabinoid receptors; Dopamine; Dyspepsia; Ferret; Gamma amino butyric acid; Gastroesophageal reflux disease; Ghrelin; Muscarinic receptor antagonists; Nausea; Opioid receptors; Substance P; Vomiting

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; AM 221; ANTIHISTAMINIC AGENT; APREPITANT; CANNABINOID RECEPTOR AGONIST; CHLORPROMAZINE; CINNARIZINE; CORTICOSTEROID; CYCLIZINE; DEXAMETHASONE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; FLUPHENAZINE; GHRELIN; GRANISETRON; HALOPERIDOL; MECLOZINE; METOCLOPRAMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; NABILONE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; OPIATE AGONIST; PROCHLORPERAZINE; PROMETHAZINE; RIMONABANT; SCOPOLAMINE; SEROTONIN 1A AGONIST; SEROTONIN 3 RECEPTOR; THIETHYLPERAZINE; UNINDEXED DRUG;

APPETITE; BRAIN STEM; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; LOWER ESOPHAGUS SPHINCTER; MOTION SICKNESS; NAUSEA; NONHUMAN; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; REVIEW; VAGUS NERVE; VOMITING;

ANIMALS; ANTIEMETICS; BRAIN; HUMANS; NAUSEA; VOMITING;

EID: 33749170154     PISSN: 15660702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autneu.2006.07.009     Document Type: Review

References (108)

1. 3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 69 (2005) 97-109
2. Aaapro M., and Alberts D.S. High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother. Pharmacol. 7 (1981) 11-14
3. Abrahamsson H., and Thoren P. Vomiting and reflex vagal relaxation of the stomach elicited from heart receptors in the cat. Acta Physiol. Scand. 88 (1973) 433-439
4. Alfieri A.B., and Cubeddu L.X. Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients. Br. J. Cancer 72 (1995) 1013-1015
5. Andrews P.L.R., and Horn C.C. Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton. Neurosci. 125 (2006) 100-115
6. Andrews P.L.R., and Lawes N. In: Ritter S., et al. (Ed). Neuroanatomy and Physiology of Abdominal Vagal Afferents (1992), CRC press 280-302
7. 1 receptor in nausea and emesis. In: Holzer P. (Ed). Handbook of Experimental Pharmacology (2004), Springer, Tachykinins 359-440
8. Andrews P.L.R., and Sanger G.J. Emesis and Anti-cancer Therapy: Mechanisms and Treatment (1993), Chapman and Hall Medical, London
9. Andrews P., Morrow G., Hickock J., Roscoe J., and Stone P. Mechanisms and models of fatigue associated with cancer and its treatment: evidence from preclinical and clinical studies. In: Armes J., Krishnasamy M., and Higginson I. (Eds). Fatigue in Cancer (2004), Oxford University Press, Oxford, U.K. 51-87
10. Apfel C.C., Korttila K., Abdalla M., Kerger H., Turan A., Vedder I., Zernak C., Danner K., Jokela R., Pockock S.J., Trenkler S., Kredel M., Biedler A., Sessler D.J., Roewer N., and IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N. Engl. J. Med. 350 (2004) 2441-2451
11. Axelsson P., Thorn S.E., and Wattwil M. Betamethasone does not prevent nausea and vomiting induced by ipecacuanha. Acta Anaesthesiol. Scand. 48 (2003) 1283-1286
12. Baker J.J., Lokey J.L., Price N.A., Winokur S.H., Bowen J., and Taylor A. Letter. N. Engl. J. Med. 301 (1979) 728
13. Blatteis C.M., and Li S. Pyrogenic signaling via vagal afferents: what stimulates their receptors?. Auton. Neurosci. Basic Clin. 85 (2000) 66-71
14. Bountra, C., Bays, D.E. 1998. Use of GABA agonists for treating emesis. United States Patent, 5.719, 185.
15. Carpenter D.O., Briggs D.B., Knox A.P., and Strominger N.L. Excitation of area postrema neurons by transmitters, peptides and cyclic nucleotides. J. Neurophysiol. 59 (1988) 358-369
16. Chial H.J., Camilleri M., Burton D., Thomforde G., Olden K.W., and Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am. J. Physiol. 284 (2003) G130-G137
17. Clarke R.S.J., and Dundee J.W. Side effects of anti-emetics: results of a class experiment. Eur. J. Pharmacol. 14 (1971) 291-300
18. Costall B., Domeney A.M., Naylor R.J., and Tattersall F.D. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25 (1986) 959-961
19. Costello D.J., and Borison H.L. Naloxone antagonizes narcotic self blockade of emesis in the cat. J. Pharmacol. Exp. Ther. 203 (1977) 222-230
20. 1 receptor antagonist/inverse agonist SR141716A. Neuropsychopharmacology 24 (2001) 198-203
21. 3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew). J. Neural Transm. 106 (1999) 1045-1061
22. Dass N.B., Monunyara M., Bassil A.K., Hervieu G.J., Osbourne S., Corcoran S., Morgan M., and Sanger G.J. Growth hormone secretagogue receptors in the rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience 120 (2003) 443-453
23. Davis C.J. Emesis research: a concise history of the critical concepts and experiments. In: Reynolds D.J.M., Andrews P.L.R., and Davis C.J. (Eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy (1995), Oxford Clinical Communications, Oxford, U.K. 9-24
24. de Wit R., Aapro M., and Blower P.R. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?. Cancer Chemother. Pharmacol. 56 (2005) 231-238
25. Ebenezer I.S., and Pringle A.K. The effect of systemic administration of baclofen on food intake in rats. Neuropharmacology 31 (1992) 39-42
26. 3 receptors in rat nodose ganglion neurons. J. Neurophysiol. 73 (1995) 907-910
27. Florczyk A.P., Schurig J.E., and Bradner W.T. Cisplatin-induced emesis in the ferret: a new animal model. Cancer Treat. Rep. 66 (1982) 187-189
28. Foubert J., and Vaessen G. Nausea: the neglected symptom?. Eur. J. Oncol. Nurs. 9 (2005) 21-32
29. Franzese A., Borelli O., Corrado G., Rea P., Di Nardo G., Grandinetti A.L., Dito L., and Cucchiara S. Domperidone is more effective than cisapride in children with diabetic gastroparesis. Aliment. Pharmacol. Ther. 16 (2002) 951-957
30. Gershon M.D. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment. Pharmacol. Ther. 13 Suppl 2 (1999) 15-30
31. 3 Receptor Subunits (HTR3C-E). Proceedings of the British Pharmacology Society at http://www.pa2online.org/abstracts/Vol3Issue4abst177P.
32. Ginzel K.H., Eldred E., Watanabe S., and Grover F. Drug-induced depression of gamma efferent activity. 3. Viscero-somatic reflex action of phenyldiguanide, veratridine and 5-hydroxytryptamine. Neuropharmacology 10 (1971) 77-91
33. Goehler L.E., Gaykema R.P., Hansen M.K., Anderson K., Maier S.F., and Watkins L.R. Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton. Neurosci. 85 (2000) 49-59
34. Golding J.F., and Stott J.R. Comparison of the effects of a selective muscarininc receptor antagonist and hyoscine (scopolamine)on motion sickness, skin conductance and heart rate. Br. J. Clin. Pharmacol. 43 (1997) 633-637
35. Gralla R.J., Itri L.M., Pisko S.E., et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 305 (1981) 905-909
36. Gralla R.J., Osoba D., Kris M.G., et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J. Clin. Oncol. 17 (1999) 2971-2994
37. Grundy G. Signalling the state of the digestive tract. Auton. Neurosci. 125 (2006) 76-80
38. 2 receptors in cisplatin-induced emesis in dogs. Indian J. Physiol. Pharmacol. 46 (2002) 463-467
39. Hesketh P.J., Van B.S., Aapro M., Tattersall F.D., Naylor R.J., Hargreaves R., Carides A.D., Evans J.K., and Horgan K.J. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Cancer 39 (2003) 1074-1080
40. Hornby P.J. Central neurocircuitry associated with emesis. Am. J. Med. 111 8A (2001) 106S-112S
41. Hursti T.J., Fredrikson M., Steineck G., Borjeson S., Furst C.J., and Peterson C. Endogenous cortisol exerts antiemetic effects similar to that of endogenous corticosteroids. Br. J. Cancer 68 (1993) 112-114
42. 4 receptor subtypes in human dorsal vagal complex. Synapse 24 (1996) 224-232
43. Inoue A., Yamada Y., Matsumura Y., Shimada Y., Muro K., Gotoh M., Hamaguchi T., Mizuno T., and Shiraz K. Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support. Care Cancer 11 (2003) 528-532
44. 1A receptor-mediated gastric relaxation in conscious dogs. Br. J. Pharmacol. 140 (2003) 913-920
45. Kamovsky A.M., Gotow L.F., McKinley D.D., Piechan J.L., Ruble C.L., Mills C.J., Schellin K.A.B., Slightom J.L., Fitzgerald L.R., Benjamin C.W., and Roberds S.L. A cluster of novel serotonin receptor 3-like genes on human chromosome 3. Gene 319 (2003) 137-148
46. Kawai M., Kawahara H., Hirayama S., Yoshimura N., and Ida S. Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. J. Pediatr. Gastroenterol. Nutr. 38 (2004) 317-323
47. Kaya N., Shen T., Lu S., Zhao F., and Herness S. A paracrine signaling role for serotonin in rat taste buds:expression and localization of serotonin receptor subtypes. Am. J. Physiol., Regul. Integr. Comp. Physiol. 286 (2004) 649-658
48. Kent S., Bluthe R.-M., Kelley K.W., and Dantzer R. Sickness behaviour as a new target for drug development. Trends Pharmacol. Sci. 13 (1992) 24-28
49. Kris M.G., hesketh P.J., Herrstedt J., Rittenberg C., Einhorn L.H., Grunberg S., Koeller J., Olver I., Borjeson S., and Ballatori E. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-risk chemotherapy. Support. Care Cancer 13 (2005) 85-96
50. Krylatov A.V., Maslov L.N., Lasukova O.V., and Pertwee R.G. Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonists in experiments on isolated perfused rat heart. Bull. Exp. Biol. Med. 139 (2005) 558-561
51. Lapierre Y.D., Silverstone P., Reesal R.T., Saxena B., Turner P., Bakish D., Plamondon J., Vincent P.M., Remick R.A., Kroft C., Payeur R., Rosales D., Lam R., and Bologa M. A Canadian multicenter study of three fixed doses of controlled release ipsapirone in outpatients with moderate to severe depression. J. Clin. Psychopharmacol. 18 (1998) 268-273
52. B receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 117 (1999) 1147-1154
53. Lehmann A., Blackshaw L.A., Branden L., Carlsson A., Jensen J., Nygren E., and Smid S.D. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 123 (2002) 1129-1134
54. Lever I.J., and Malcangio M. CB1 receptor antagonist SR141716A increases capsaicin-evoked release of substance P from the adult mouse spinal cord. Br. J. Pharmacol. 135 (2002) 21-24
55. Li B., and Misiewicz L. Cyclic vomiting syndrome: a brain-gut disorder. Gastroenterol. Clin. North Am. 32 (2003) 997-1019
56. Liu Y.-L., Malik N., Sanger G.J., and Andrews P.L.R. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in mice. Cancer Chemother. Pharmacol. 58 (2006) 326-333
57. Lucot J.B. Effects of serotonin antagonists on motion sickness and its suppression by 8-OH-DPAT in cats. Pharmacol. Biochem. Behav. 37 (1990) 283-287
58. Lucot J.B. Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin. Eur. J. Pharmacol. 253 (1994) 53-60
59. Malik N.M., Moore G.B., Smith G., Liu Y.L., Sanger G.J., and Andrews P.L. Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: a model for chemotherapy related malaise?. Pharmacol. Biochem. Behav. 83 (2006) 9-20
60. Miner W.J., and Sanger G.J. Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br. J. Pharmacol. 88 (1986) 497-499
61. qo5. Biochem. Pharmacol. 68 (2004) 761-772
62. Mitchelson F. Pharmacological agents affecting emesis. A review (Part 1). Drugs 43 (1992) 295-315
63. 3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 310 (2003) 101-111
64. 1A receptor agonists in Suncus murinus. Jpn. J. Pharmacol. 64 (1994) 109-114
65. 4, receptor agonists are emetogenic in ferrets. Pharmacol. Biochem. Behav. 81 (2005) 211-219
66. B receptors involves calcium and potassium channels. Neurosci. 137 (2006) 627-636
67. Parker, L.A., Limebeer, C.L., Kwaitkowska, M., 2005. Cannabinoids: effects on vomiting and nausea in animal models. In: Mechoulam, R. (Ed.), Cannabinoids as Therapeutics. Birkhauser Verlag/Switzerland, pp. 183-200.
68. Peeters T.L. Ghrelin: a new player in the control of gastrointestinal functions. Gut 54 (2005) 1638-1649
69. Penagini R., and Bianchi P.A. Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology 113 (1997) 409-414
70. Peroutka S.J., and Snyder S.H. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 2 (1982) 658-659
71. 3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised double blind, placebo controlled study. Gut 54 (2005) 1169-1173
72. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J., and RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J. Am. Med. Assoc. 295 (2006) 761-775
73. Racke K., Schworer H., and Kilbinger H. The pharmacology of 5-HT release from enterochromaffin cells. In: Reynolds D.J.M., Andrews P.L.R., and Davis C.J. (Eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy (1995), Oxford Clinical Communications, Oxford, U.K. 84-89
74. 3e receptor subunits to the gastrointestinal tract of humans and other species. Neurogastroenterol. Motil. 17 s2 (2005) 69
75. Rich W.M., Abdulhayoglu G., and DiDaia P.J. Methylprednisolone as an antienetic during cancer chemotherapy-a pilot study. Gynecol. Oncol. 9 (1980) 193-198
76. Rosenberg B., Van Camp L., Trosko J.E., and Mansour V.H. Platinum compounds: a new class of potent antitumour agent. Nature 222 (1969) 385-386
77. Rudd J.A., and Andrews P.L.R. Mechanisms of acute, delayed, and anticipatory emesis induced by anticancer therapies. In: Hesketh P.J. (Ed). Management of Nausea and Vomiting in Cancer and Cancer Treatment (2005), Jones and Bartlett, Sudbury, MA 15-65
78. Rudd J.A., and Naylor R.J. Opioid receptor involvement in emesis and antiemesis. In: Reynolds D.J.M., Andrews P.L.R., and Davis C.J. (Eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy (1995), Oxford Clinical Communications, Oxford, U.K. 208-221
79. Rudd J.A., Cheng C.H., Naylor R.J., Ngan M.P., and Wai M.K. Modulation of emesis by fentanyl and apioid receptor antagonist in Suncus murinus (house musk shrew). Eur. J. Pharmacol. 374 (1999) 77-84
80. Rudd J.A., Ngan M.P., Wai M.K., King A.G., Witherington J., Andrews P.L.R., and Sanger G.J. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci. Lett. 392 (2006) 79-83
81. Sam T.S.W., Kan K.K.W., Ngan M.P., Rudd J.A., and Yeung J.H.K. Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret. Eur. J. Pharmacol. 466 (2003) 163-168
82. Sanger G.J. Effects of metoclopramide and domperidone on cholinergically-mediated contractions of human isolated stomach muscle. J. Pharm. Pharmacol. 37 (1985) 661-664
83. 3 receptor antagonist characteristics. In: Reynolds D.J.M., Andrews P.L.R., and Davis C.J. (Eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy (1995), Oxford Clinical Communications, Oxford, U.K. 155-163
84. Sanger G.J., and Andrews P.L.R. Emesis. In: Farthing M.J.G., and Ballinger A.B. (Eds). Drug Therapy for Gastrointestinal and Liver Disease (2001), Martin Dunitz Ltd, London 45-61
85. Sharpe M., Clements A., Hawton K., Young A.H., Sargent P., and Cowen P.J. Increased prolactin response to buspirone in chronic fatigue syndrome. J. Affect. Disord. 41 (1996) 71-76
86. Soderpalm A.H.V., Schuster A., and de Wit H. Antiemetic efficacy of smoked marijuana-subjecive and behavioural effects on nausea induced by syrup of ipecac. Pharmacol. Biochem. Behav. 69 (2001) 342-350
87. 3 receptor antagonists-preliminary results. Scand. J. Rheumatol. 29 Suppl 113 (2000) 72-77
88. Stern R.M., Hu S., Uijtdehaage S.H., Muth F.R., Xu L.H., and Koch K.L. Asian hypersusceptibility to motion sickness. Hum. Hered. 46 (1996) 7-14
89. Stone P., Richards M., and Hardy J. Fatigue in patients with cancer. Eur. J. Cancer 34 (1998) 1670-1676
90. Suchitra A.D., Dkhar S.A., Shewade D.G., and Shashindran C.H. Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in mice. World J. Gastroenterol. 9 (2003) 779-783
91. B receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects. Neuropharmacology 49 (2005) 1121-1131
92. The Antiemetic Subcommittee of the Multinational Association of Supportive care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann. Oncol. 17 (2006) 20-28
93. Thompson P.I., Bingham S., Andrews P.L.R., Paterl N., Joel S.P., and Slevin M. Morphine-6-glucuronide-a metabolite of morphine with greater emetic potency than morphine in the ferret. Br. J. Pharmacol. 106 (1992) 3-8
94. Tonini M., Cipollina L., Poluzzi E., Crema F., Corazza G.R., and De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment. Pharmacol. Ther. 19 (2004) 379-390
95. Tougas G., and Banemai M. Gastroesophageal reflux disease pathophysiology. Chest Surg. Clin. North Am. 11 (2001) 485-494
96. Tramer M.R., Reynolds D.J.M., Stoner N.S., Moore R.A., and McQuay H.J. Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting:a quantitative systematic review. Eur. J. Cancer 34 (1998) 1836-1844
97. Travagli R.A., Hermann G.E., Browning K.N., and Rogers R.C. Brainstem circuits regulating gastric function. Annu. Rev. Physiol. 68 (2006) 279-305
98. Tremblay P.-B., Kaiser R., Sezer O., Rosler N., Schelenz C., Possinger K., Roots I., and Brockmoller J. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J. Clin. Oncol. 21 (2003) 2147-2155
99. Van Sickle M.D., Oland L.D., Ho W., Hillard C.J., Mackie K., Davidson J.S., and Sharley K.A. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121 (2001) 767-774
100. Van Sickle M.D., Oland L.D., Ho W., Hillard C.J., Mackie K., Davidson J.S., and Sharley K.A. Tetrahydrocannabinol selectively acts o CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am. J. Physiol.: Gasterointest. Liver Physiol. 285 (2003) G566-G576
101. van Vliet I.M., Slaap V.R., Westenberg H.G.M., and Den Boer J.A. Behavioural, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder. Eur. J. Neuropsychopharmacol. 6 (1996) 103-110
102. Warr D.G., Hesketh P.J., Gralla R.J., Muss H.B., Herrstedt J., Eisenberg P.D., Raftopoulos H., Grunberg S.M., Gabriel M., Rodgers A., Bohidar N., Klinger G., Hustad C.M., Horgan K., and Skobieranda F. Efficacy and tolerability of aprepitant for the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. 23 (2005) 2822-2830
103. Wiley J.L., Burston J.J., Leggett D.C., Alekseeva O.O., Razdan R.K., Mahadevan A., and Martin B.R. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br. J. Pharmacol. 145 (2005) 293-300
104. Wilson W.M., and Maughan R.J. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT reuptake inhibitor, reduces the capacity to perform prolonged exercise. Exp. Physiol. 77 (1992) 921-924
105. 1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting. Eur. J. Pharmacol. 340 (1997) 217-220
106. Yates B.J., Miller A.D., and Lucot J.B. Physiological basis and pharmacology of motion sickness. Brain Res. Bull. 47 (1998) 395-406
107. 3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret. Eur. J. Pharmacol. 301 (1996) 143-149
108. Zabara J., Chaffee R.B., and Tansy M.F. Neuroinihibition in the regulation of emesis. Space Life Sci. 3 (1972) 282-292